Özlem Sönmez

Abstract PS4-11-08: Clinical characteristics and prognosis in interval detected breast cancer patients: a single institution cohort analysis

Yeşim Eralp, Serra Bayrakceken, K. Turker Karayazi, G. Esen Icten et autres

Abstract Aim: The aim of this study is to identify clinical characteristics and outcomes in a cohort of patients with interval-detected breast cancers. Methods: Interval-detected cancers were tumors that arose within a year of the last screening breast imaging that appeared normal, …

tr (code pays fourni par la source)

Cognitive Impairment in Caregivers of Cancer Patients: A Cross-sectional Study

Elif Şenocak Taşçı, Aziz Yazar, Ömer Orhun, Müjdat Kara et autres

Aim: Cancer caregivers (CCG) is crucial in well-being of patients with cancer.They are responsible for making cognitively demanding decisions that affect patients' welfare.In this study, we aimed to evaluate the cognitive impairment of CCG and compare with non-CCG.Methods: This cross-sectional study focused …

Assessment of health literacy and HPV knowledge among university students: An observational study

Elif Şenocak Taşçı, Dilşat Baş, Simge Kayak, Sema Anik et autres

Health literacy (HL) level is related to promotion of health, improved health behaviors, and early diagnosis of diseases, as well as the appropriate use of health services. Human papillomavirus (HPV) vaccination is the primary method of protection against cervical cancer and recommended …

tr (code pays fourni par la source)

Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study

Elif Şenocak Taşçı, Yasin Kutlu, Ömer Fatih Ölmez, Arda Ulaş Mutlu et autres

Background Triple negative breast cancer (TNBC) is characterized by high rates of recurrence, especially in patients with residual disease after neoadjuvant chemotherapy (NAC). Capecitabine is being used as standard adjuvant treatment in residual TNBC. We aimed to investigate the real-life data regarding …

tr (code pays fourni par la source)

Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

Elif Şenocak Taşçı, Başak Oyan, Özlem Sönmez, Arda Ulaş Mutlu et autres

Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

tr (code pays fourni par la source)

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

Elif Şenocak Taşçı, Başak Oyan, Özlem Sönmez, Arda Ulaş Mutlu et autres

BACKGROUND: The optimal treatment for metastatic colorectal cancer (mCRC) after the second line is still controversial. Regorafenib has been the standard of care in this setting as it improved overall survival (OS) compared to placebo. In real-world practice chemotherapy rechallenge is also …

tr (code pays fourni par la source)

Is virtual nutritional counseling efficacious for cancer patients during the COVID-19 pandemic?

Dilşat Baş, Özlem Sönmez, Elif Sitre Koç, Özde Melisa Celayir et autres

This study investigates the outcomes of virtual nutritional counseling (VNC) for oncology patients during the Covid-19 pandemic. Our study evaluated the nutritional status data of cancer patients at the baseline and after VNC. An oncology dietitian evaluated the patients by video calling …

tr, us (code pays fourni par la source)

Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Cengiz Karaçin, Berna Öksüzoğlu, Ayşe Demirci, Merve Keskinkılıç et autres

tr (code pays fourni par la source)

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Cengiz Karaçin, Berna Öksüzoğlu, Ayşe Demirci, Merve Keskinkılıç et autres

BACKGROUND: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In …

tr (code pays fourni par la source)

Validation of bioelectrical impedance analysis in the evaluation of body composition in patients with breast cancer

Dilşat Baş, Erkin Arıbal, Erkan Vardareli̇, Özlem Sönmez et autres

BACKGROUND: The evaluation of body composition is an essential parameter for preventing obesity and sarcopenic obesity, which are prognostic factors in breast cancer. This study aims to validate the bioelectrical impedance analysis (BIA) of women who are breast cancer survivors by using …

tr (code pays fourni par la source)

EE193 The Health Impact Projection Model of the PD-1/PD-L1 Inhibitor Class in Cancer Care in Turkey

U Akpamuk, Robert Hughes, O. Swales, Başak Oyan et autres

gb, tr, de (code pays fourni par la source)

The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study

Özlem Özdemir, Baha Zengel, Yaşar Yıldız, Başak Oyan Uluç et autres

In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology Group (TOG) with data …

tr, co, cy (code pays fourni par la source)